132 related articles for article (PubMed ID: 35316624)
1. Prognostic biomarkers in primary progressive multiple sclerosis: Validating and scrutinizing multimodal evoked potentials.
Hardmeier M; Schlaeger R; Lascano AM; Toffolet L; Schindler C; Gobbi C; Lalive P; Kuhle J; Kappos L; Fuhr P
Clin Neurophysiol; 2022 May; 137():152-158. PubMed ID: 35316624
[TBL] [Abstract][Full Text] [Related]
2. Validation of Quantitative Scores Derived From Motor Evoked Potentials in the Assessment of Primary Progressive Multiple Sclerosis: A Longitudinal Study.
Hardmeier M; Schindler C; Kuhle J; Fuhr P
Front Neurol; 2020; 11():735. PubMed ID: 32793104
[No Abstract] [Full Text] [Related]
3. Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis.
Schlaeger R; D'Souza M; Schindler C; Grize L; Kappos L; Fuhr P
Mult Scler; 2014 Jan; 20(1):51-6. PubMed ID: 23756680
[TBL] [Abstract][Full Text] [Related]
4. The utility of multimodal evoked potentials in multiple sclerosis prognostication.
Ramanathan S; Lenton K; Burke T; Gomes L; Storchenegger K; Yiannikas C; Vucic S
J Clin Neurosci; 2013 Nov; 20(11):1576-81. PubMed ID: 23827173
[TBL] [Abstract][Full Text] [Related]
5. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis.
Kallmann BA; Fackelmann S; Toyka KV; Rieckmann P; Reiners K
Mult Scler; 2006 Feb; 12(1):58-65. PubMed ID: 16459720
[TBL] [Abstract][Full Text] [Related]
6. Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis.
Giffroy X; Maes N; Albert A; Maquet P; Crielaard JM; Dive D
BMC Neurol; 2016 Jun; 16():83. PubMed ID: 27245221
[TBL] [Abstract][Full Text] [Related]
7. Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy.
Iodice R; Carotenuto A; Dubbioso R; Cerillo I; Santoro L; Manganelli F
J Neurol Sci; 2016 Jun; 365():143-6. PubMed ID: 27206893
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score.
Invernizzi P; Bertolasi L; Bianchi MR; Turatti M; Gajofatto A; Benedetti MD
J Neurol; 2011 Nov; 258(11):1933-9. PubMed ID: 21479648
[TBL] [Abstract][Full Text] [Related]
9. Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?
Giffroy X; Maes N; Albert A; Maquet P; Crielaard JM; Dive D
Acta Neurol Belg; 2017 Mar; 117(1):53-59. PubMed ID: 27194163
[TBL] [Abstract][Full Text] [Related]
10. Visual and motor evoked potentials in the course of multiple sclerosis.
Fuhr P; Borggrefe-Chappuis A; Schindler C; Kappos L
Brain; 2001 Nov; 124(Pt 11):2162-8. PubMed ID: 11673318
[TBL] [Abstract][Full Text] [Related]
11. Motor evoked potentials and disability in secondary progressive multiple sclerosis.
Facchetti D; Mai R; Micheli A; Marcianó N; Capra R; Gasparotti R; Poloni M
Can J Neurol Sci; 1997 Nov; 24(4):332-7. PubMed ID: 9398981
[TBL] [Abstract][Full Text] [Related]
12. Prediction of long-term disability in multiple sclerosis.
Schlaeger R; D'Souza M; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P
Mult Scler; 2012 Jan; 18(1):31-8. PubMed ID: 21868486
[TBL] [Abstract][Full Text] [Related]
13. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.
Jung P; Beyerle A; Ziemann U
Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509
[TBL] [Abstract][Full Text] [Related]
14. Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval?
Schlaeger R; D'Souza M; Schindler C; Grize L; Kappos L; Fuhr P
Clin Neurophysiol; 2014 Sep; 125(9):1889-92. PubMed ID: 24555924
[TBL] [Abstract][Full Text] [Related]
15. Early disturbances in multimodal evoked potentials as a prognostic factor for long-term disability in relapsing-remitting multiple sclerosis patients.
London F; El Sankari S; van Pesch V
Clin Neurophysiol; 2017 Apr; 128(4):561-569. PubMed ID: 28231474
[TBL] [Abstract][Full Text] [Related]
16. Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study.
Leocani L; Rovaris M; Boneschi FM; Medaglini S; Rossi P; Martinelli V; Amadio S; Comi G
J Neurol Neurosurg Psychiatry; 2006 Sep; 77(9):1030-5. PubMed ID: 16735397
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
Baeva ME; Tottenham I; Koch M; Camara-Lemarroy C
J Neuroimmunol; 2024 Feb; 387():578268. PubMed ID: 38157653
[TBL] [Abstract][Full Text] [Related]
18. Multimodal Evoked Potentials as Candidate Prognostic and Response Biomarkers in Clinical Trials of Multiple Sclerosis.
Hardmeier M; Fuhr P
J Clin Neurophysiol; 2021 May; 38(3):171-180. PubMed ID: 33958567
[TBL] [Abstract][Full Text] [Related]
19. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
20. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
Fissolo N; Benkert P; Sastre-Garriga J; Mongay-Ochoa N; Vilaseca-Jolonch A; Llufriu S; Blanco Y; Hegen H; Berek K; Perez-Miralles F; Rejdak K; Villar LM; Monreal E; Alvarez-Lafuente R; Soylu OK; Abdelhak A; Bachhuber F; Tumani H; Martínez-Yélamos S; Sánchez-López AJ; García-Merino A; Gutiérrez L; Castillo-Trivino T; Lycke J; Rosenstein I; Furlan R; Filippi M; Téllez N; Ramió-Torrentà L; Lünemann JD; Wiendl H; Eichau S; Khalil M; Kuhle J; Montalban X; Comabella M
J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):410-418. PubMed ID: 37940409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
